Prestige Consumer Healthcare Inc. (PBH) Q1 2026 Earnings Call Transcript

Prestige Consumer Healthcare (PBH) reported a disappointing Q1 FY26 with revenue of $249.5 million, missing forecasts and declining 6.6% year-over-year, primarily due to a prolonged production shutdown impacting its Clear Eyes brand. Despite the sales miss, EPS grew 6% to $0.95, aided by a 150 basis point gross margin expansion and lower interest expense. To address persistent supply chain issues for Clear Eyes, PBH announced the acquisition of its primary supplier, Pillar5 Pharma, for approximately $100 million, aiming to secure and expand long-term production capacity, with significant recovery expected in H2 FY26. Consequently, the company revised its full-year FY26 revenue guidance down to $1.1-$1.115 billion (organic decline of 1.5%-3%) and adjusted EPS to $4.50-$4.58 (flat to 1% growth), while maintaining its free cash flow outlook of $245 million or more.

Analysis

Prestige Consumer Healthcare (PBH) reported a challenging first quarter for fiscal 2026, with revenues of $249.5 million missing the company's forecast and declining 6.6% year-over-year. The primary cause for this underperformance was a severe supply constraint for its key Clear Eyes brand, stemming from a prolonged production shutdown at a supplier, which overshadowed positive momentum in other areas. Notably, the International segment grew 7.1% organically and the Summer's Eve brand continued its recovery. Despite the top-line miss, the company demonstrated operational efficiency, expanding gross margin by 150 basis points to 56.2% and delivering a record $78 million in free cash flow. This, along with marketing timing and lower interest expense, resulted in a 6% increase in adjusted EPS to $0.95. In a decisive strategic move to address the root cause of its issues, PBH announced the acquisition of its primary eye care supplier, Pillar5 Pharma, for approximately $100 million. This vertical integration aims to secure and expand production capacity, with management anticipating a meaningful supply recovery in the second half of the fiscal year. Consequently, PBH has lowered its full-year guidance, now forecasting revenue of $1.1-$1.115 billion (a 1.5% to 3% organic decline) and adjusted EPS of $4.50-$4.58 (flat to 1% growth), citing both the first-half eye care shortfall and increased volatility in retail ordering patterns.

Key Decisions for Investors

• Investors should anticipate continued near-term pressure on the stock, as the revised full-year guidance reflects significant operational headwinds in the first half from both Clear Eyes supply issues and volatile retail ordering.
• The acquisition of Pillar5 is a critical de-risking event; its successful integration and the ramp-up of a new high-speed production line in Q3 are the key catalysts to monitor for a return to growth in the second half and into fiscal 2027.
• Despite the operational challenges, the company's strong financial fundamentals, including a record $78 million in Q1 free cash flow, a stable 2.4x leverage ratio, and ongoing share repurchases, provide a measure of downside protection.
• Monitor the market share data for Clear Eyes and management's commentary on retailer inventory levels in the coming quarters, as recovery of lost distribution and normalization of order patterns will be crucial for validating the long-term investment thesis.